Rights and permissions
About this article
Cite this article
Victoza likely to make Bydureon's market entry difficult. Pharmacoecon. Outcomes News 624, 11 (2011). https://doi.org/10.1007/BF03295180
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03295180